Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case–control study

Anton Pottegård, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Chaw Ning Lee, Chao Kai Hsu, Tzu Chi Liao, Shih Chieh Shao, Edward Chia Cheng Lai

Research output: Contribution to journalArticle

Abstract

Background: The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes. Previous studies were, however, conducted in predominantly Caucasian populations. We therefore examined the association between hydrochlorothiazide and skin cancer risk in an Asian population. Methods: By using Taiwan’s National Health Insurance Research Database (NHIRD), we conducted three separate case–control studies of lip cancer, non-lip non-melanoma skin cancer and melanoma. Cases (n = 29,082) with a first-ever skin cancer diagnoses (2008–2015) were matched 1:10 to population controls. We estimated odds ratios (ORs) associating hydrochlorothiazide use with skin cancer risk by using conditional logistic regression. Results: Hydrochlorothiazide use showed no overall association with any of the three outcomes: ORs for high cumulative use of HCTZ (≥50,000 mg) were 0.86 (95% CI 0.09–7.81) for lip cancer, 1.16 (95% CI 0.98–1.37) for non-lip NMSC and 1.07 (95% CI 0.65–1.76) for melanoma. There was some evidence of a dose–response pattern for non-lip NMSC, with an OR of 1.66 (95% CI 0.82–3.33) for 100,000–149,999 mg of HCTZ. The null findings were robust across subgroup and sensitivity analyses. Conclusion: Use of HCTZ appears safe in terms of skin cancer risk in an Asian population.

Original languageEnglish
Pages (from-to)973-978
Number of pages6
JournalBritish Journal of Cancer
Volume121
Issue number11
DOIs
Publication statusPublished - 2019 Nov 26

Fingerprint

Hydrochlorothiazide
Skin Neoplasms
Lip Neoplasms
Melanoma
Odds Ratio
Population
Population Control
National Health Programs
Antihypertensive Agents
Logistic Models
Databases
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Pottegård, Anton ; Pedersen, Sidsel Arnspang ; Schmidt, Sigrun Alba Johannesdottir ; Lee, Chaw Ning ; Hsu, Chao Kai ; Liao, Tzu Chi ; Shao, Shih Chieh ; Lai, Edward Chia Cheng. / Use of hydrochlorothiazide and risk of skin cancer : a nationwide Taiwanese case–control study. In: British Journal of Cancer. 2019 ; Vol. 121, No. 11. pp. 973-978.
@article{d365b16b55b24911b1c78683aa5f24db,
title = "Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case–control study",
abstract = "Background: The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes. Previous studies were, however, conducted in predominantly Caucasian populations. We therefore examined the association between hydrochlorothiazide and skin cancer risk in an Asian population. Methods: By using Taiwan’s National Health Insurance Research Database (NHIRD), we conducted three separate case–control studies of lip cancer, non-lip non-melanoma skin cancer and melanoma. Cases (n = 29,082) with a first-ever skin cancer diagnoses (2008–2015) were matched 1:10 to population controls. We estimated odds ratios (ORs) associating hydrochlorothiazide use with skin cancer risk by using conditional logistic regression. Results: Hydrochlorothiazide use showed no overall association with any of the three outcomes: ORs for high cumulative use of HCTZ (≥50,000 mg) were 0.86 (95{\%} CI 0.09–7.81) for lip cancer, 1.16 (95{\%} CI 0.98–1.37) for non-lip NMSC and 1.07 (95{\%} CI 0.65–1.76) for melanoma. There was some evidence of a dose–response pattern for non-lip NMSC, with an OR of 1.66 (95{\%} CI 0.82–3.33) for 100,000–149,999 mg of HCTZ. The null findings were robust across subgroup and sensitivity analyses. Conclusion: Use of HCTZ appears safe in terms of skin cancer risk in an Asian population.",
author = "Anton Potteg{\aa}rd and Pedersen, {Sidsel Arnspang} and Schmidt, {Sigrun Alba Johannesdottir} and Lee, {Chaw Ning} and Hsu, {Chao Kai} and Liao, {Tzu Chi} and Shao, {Shih Chieh} and Lai, {Edward Chia Cheng}",
year = "2019",
month = "11",
day = "26",
doi = "10.1038/s41416-019-0613-4",
language = "English",
volume = "121",
pages = "973--978",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

Use of hydrochlorothiazide and risk of skin cancer : a nationwide Taiwanese case–control study. / Pottegård, Anton; Pedersen, Sidsel Arnspang; Schmidt, Sigrun Alba Johannesdottir; Lee, Chaw Ning; Hsu, Chao Kai; Liao, Tzu Chi; Shao, Shih Chieh; Lai, Edward Chia Cheng.

In: British Journal of Cancer, Vol. 121, No. 11, 26.11.2019, p. 973-978.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of hydrochlorothiazide and risk of skin cancer

T2 - a nationwide Taiwanese case–control study

AU - Pottegård, Anton

AU - Pedersen, Sidsel Arnspang

AU - Schmidt, Sigrun Alba Johannesdottir

AU - Lee, Chaw Ning

AU - Hsu, Chao Kai

AU - Liao, Tzu Chi

AU - Shao, Shih Chieh

AU - Lai, Edward Chia Cheng

PY - 2019/11/26

Y1 - 2019/11/26

N2 - Background: The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes. Previous studies were, however, conducted in predominantly Caucasian populations. We therefore examined the association between hydrochlorothiazide and skin cancer risk in an Asian population. Methods: By using Taiwan’s National Health Insurance Research Database (NHIRD), we conducted three separate case–control studies of lip cancer, non-lip non-melanoma skin cancer and melanoma. Cases (n = 29,082) with a first-ever skin cancer diagnoses (2008–2015) were matched 1:10 to population controls. We estimated odds ratios (ORs) associating hydrochlorothiazide use with skin cancer risk by using conditional logistic regression. Results: Hydrochlorothiazide use showed no overall association with any of the three outcomes: ORs for high cumulative use of HCTZ (≥50,000 mg) were 0.86 (95% CI 0.09–7.81) for lip cancer, 1.16 (95% CI 0.98–1.37) for non-lip NMSC and 1.07 (95% CI 0.65–1.76) for melanoma. There was some evidence of a dose–response pattern for non-lip NMSC, with an OR of 1.66 (95% CI 0.82–3.33) for 100,000–149,999 mg of HCTZ. The null findings were robust across subgroup and sensitivity analyses. Conclusion: Use of HCTZ appears safe in terms of skin cancer risk in an Asian population.

AB - Background: The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes. Previous studies were, however, conducted in predominantly Caucasian populations. We therefore examined the association between hydrochlorothiazide and skin cancer risk in an Asian population. Methods: By using Taiwan’s National Health Insurance Research Database (NHIRD), we conducted three separate case–control studies of lip cancer, non-lip non-melanoma skin cancer and melanoma. Cases (n = 29,082) with a first-ever skin cancer diagnoses (2008–2015) were matched 1:10 to population controls. We estimated odds ratios (ORs) associating hydrochlorothiazide use with skin cancer risk by using conditional logistic regression. Results: Hydrochlorothiazide use showed no overall association with any of the three outcomes: ORs for high cumulative use of HCTZ (≥50,000 mg) were 0.86 (95% CI 0.09–7.81) for lip cancer, 1.16 (95% CI 0.98–1.37) for non-lip NMSC and 1.07 (95% CI 0.65–1.76) for melanoma. There was some evidence of a dose–response pattern for non-lip NMSC, with an OR of 1.66 (95% CI 0.82–3.33) for 100,000–149,999 mg of HCTZ. The null findings were robust across subgroup and sensitivity analyses. Conclusion: Use of HCTZ appears safe in terms of skin cancer risk in an Asian population.

UR - http://www.scopus.com/inward/record.url?scp=85074718145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074718145&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0613-4

DO - 10.1038/s41416-019-0613-4

M3 - Article

C2 - 31673105

AN - SCOPUS:85074718145

VL - 121

SP - 973

EP - 978

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -